Should we stage all breast cancer patients before neoadjuvant chemotherapy?
Association of Breast Surgery ePoster Library. Jafferbhoy S. 05/15/17; 166234; P121
Sadaf Jafferbhoy
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Background:
Neoadjuvant chemotherapy is usually offered to patients with locally advanced breast cancer, for downsizing lesions, triple negative or HER-2 positive cancers. Staging investigations are recommended for locally advanced cancers but there are no clear guidelines for staging before neoadjuvant treatment. In our unit, computerized tomography of thorax, abdomen and pelvis and bone scan is carried out before commencing neoadjuvant chemotherapy. The aim of this study was to assess the impact of staging investigations on treatment plan.
Methods:
Retrospective data regarding staging investigations for neoadjuvant chemotherapy patients between January 2014 and December 2015 was collected and analyzed.
Results:
Out of 46 patients, 22 (48%) had locally advanced disease, 17 (37%) were HER-2 positive and 7 (15%) were triple negative cancers. Seven patients (15%) had metastatic disease on imaging. In the sub-group with locally advanced disease, the yield was 23% (5/22) whereas in early stage HER-2 positive or triple negative cases the yield was 8% (2/24).
Conclusion:
Staging investigations altered the management plan in a significant number of patients and should routinely be carried out when considering neoadjuvant chemotherapy for breast cancer.
Neoadjuvant chemotherapy is usually offered to patients with locally advanced breast cancer, for downsizing lesions, triple negative or HER-2 positive cancers. Staging investigations are recommended for locally advanced cancers but there are no clear guidelines for staging before neoadjuvant treatment. In our unit, computerized tomography of thorax, abdomen and pelvis and bone scan is carried out before commencing neoadjuvant chemotherapy. The aim of this study was to assess the impact of staging investigations on treatment plan.
Methods:
Retrospective data regarding staging investigations for neoadjuvant chemotherapy patients between January 2014 and December 2015 was collected and analyzed.
Results:
Out of 46 patients, 22 (48%) had locally advanced disease, 17 (37%) were HER-2 positive and 7 (15%) were triple negative cancers. Seven patients (15%) had metastatic disease on imaging. In the sub-group with locally advanced disease, the yield was 23% (5/22) whereas in early stage HER-2 positive or triple negative cases the yield was 8% (2/24).
Conclusion:
Staging investigations altered the management plan in a significant number of patients and should routinely be carried out when considering neoadjuvant chemotherapy for breast cancer.
Background:
Neoadjuvant chemotherapy is usually offered to patients with locally advanced breast cancer, for downsizing lesions, triple negative or HER-2 positive cancers. Staging investigations are recommended for locally advanced cancers but there are no clear guidelines for staging before neoadjuvant treatment. In our unit, computerized tomography of thorax, abdomen and pelvis and bone scan is carried out before commencing neoadjuvant chemotherapy. The aim of this study was to assess the impact of staging investigations on treatment plan.
Methods:
Retrospective data regarding staging investigations for neoadjuvant chemotherapy patients between January 2014 and December 2015 was collected and analyzed.
Results:
Out of 46 patients, 22 (48%) had locally advanced disease, 17 (37%) were HER-2 positive and 7 (15%) were triple negative cancers. Seven patients (15%) had metastatic disease on imaging. In the sub-group with locally advanced disease, the yield was 23% (5/22) whereas in early stage HER-2 positive or triple negative cases the yield was 8% (2/24).
Conclusion:
Staging investigations altered the management plan in a significant number of patients and should routinely be carried out when considering neoadjuvant chemotherapy for breast cancer.
Neoadjuvant chemotherapy is usually offered to patients with locally advanced breast cancer, for downsizing lesions, triple negative or HER-2 positive cancers. Staging investigations are recommended for locally advanced cancers but there are no clear guidelines for staging before neoadjuvant treatment. In our unit, computerized tomography of thorax, abdomen and pelvis and bone scan is carried out before commencing neoadjuvant chemotherapy. The aim of this study was to assess the impact of staging investigations on treatment plan.
Methods:
Retrospective data regarding staging investigations for neoadjuvant chemotherapy patients between January 2014 and December 2015 was collected and analyzed.
Results:
Out of 46 patients, 22 (48%) had locally advanced disease, 17 (37%) were HER-2 positive and 7 (15%) were triple negative cancers. Seven patients (15%) had metastatic disease on imaging. In the sub-group with locally advanced disease, the yield was 23% (5/22) whereas in early stage HER-2 positive or triple negative cases the yield was 8% (2/24).
Conclusion:
Staging investigations altered the management plan in a significant number of patients and should routinely be carried out when considering neoadjuvant chemotherapy for breast cancer.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}